Abstract
An inverse-shifting polymerase chain reaction (IS-PCR) combined with short-end capillary gel electrophoresis (CGE) was developed for genotyping of intron 22 inversion Type 1 (Inv22-1) and Type 2 (Inv22-2) of hemophilia A (HA). Severe HA cases are affected by intron 22 inversion around 45–50%. Inv22-1 has higher frequency than Inv22-2. The aim of this study is to distinguish them by genotyping. In order to improve Inv22 genotyping efficiency, five primers were designed and applied to differentiate the wild type, Inv22-1, Inv22-2 and carrier. Three amplicons of 405, 457 and 512bp were recognized for wild type; 333, 457 and 584bp for Inv22-1; 385, 405 and 584bp for Inv22-2. The Inv22-1 carrier has 5 amplicons including 333, 405, 457, 512, 584bp and Inv22-2 carrier is differentiated by 385, 405, 457, 512 and 584bp. The amplicons between Inv22-1 and Inv22-2 carriers are only different in 333bp for Inv22-1 carrier and 385bp for Inv22-2 carrier. Capillary gel electrophoresis (CGE) was used for separation within 5min. The separation voltage was set at 8kV (cathode at detector), and the temperature was kept at 25°C. The sieving matrix was 89mM Tris, 89mM boric acid, 2mM EDTA containing 0.4% (w/v) HPMC and 1μM of YO-PRO®-1 Iodide. Total of 50 HA patients (including 35 non-Inv22, 14 Inv22-1, and one Inv22-2 patients) and 7 HA carriers were diagnosed in the application. Seven random samples (5 patients and 2 carriers) were subjected to comparison and gave identical results of DNA sequencing and this modified IS-PCR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.